Telaprevir (VX-950) 化学構造
分子量: 679.85

品質と確認

カスタマーレビュー(4)

Quality Control & MSDS

製品情報

  • Compare HCV Protease Inhibitors
    HCV Protease阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 Telaprevir(VX-950)は、C型肝炎ウイルス(HCV)NS3-4Aセリン・プロテアーゼ阻害剤で、IC50 が0.35 μMになる。
目標 HCV NS3-4A serine protease
IC50 0.35 μM [1]
In vitro試験 Telaprevir inhibits the hepatitis C virus NS3-4A serine protease, leading to the block of viral polyprotein processing and subsequently decrease of viral RNA replication, total HCV RNA levels and protein levels in the Con1 (genotype 1b) subgenomic HCV replicon cells in a time- and dose-dependent manner. Telaprevir displays a significant time-dependent increase in inhibitory effect on the replication of HCV RNA with IC50 values of 0.574 μM, 0.488 μM, 0.210 μM and 0.139 μM for 24, 48, 72 and 120 hours incubation, respectively. Telaprevir displays an average IC50 of 0.354 μM and an average IC90 of 0.830 μM, respectively, from three independent experiments using the 48 hours incubation. Telaprevir has no significant cytotoxicity to HCV replicon cells, parental Huh-7 and HepG2 cells after 48 hours incubation. Telaprevir (17.5 μM) completely eradicates HCV RNA from replicon cells after 13 days incubation without rebound after Telaprevir is withdrawn. Telaprevir displays an additive to moderate synergistic effect on reduction of HCV RNA replication and suppression of resistance mutations without significant increase in cytotoxicity when in combination with IFN-α, compared to treatment with each agent alone. [1]
In vivo試験 Oral administration of Telaprevir reduces HCV protease-dependent cleavage and subsequent secretion of SEAP from the liver into the blood in the mice model to 18.7% and 18.4% at dosage of 10 and 25 mg/kg, respectively. [2] Administration of Telaprevir at 200 mg/kg for 1 week results in a 1.9 log reduction of HCV RNA in genotype 1b HCV-infected human hepatocyte chimeric mice, and when treatment in combination with MK-0608 (50 mg/kg) for 4 weeks, viruses are eliminated from mice. [3]
臨床試験 Currently in Phase III clinical trials in patients with Hepatitis C.
特集 Telaprevir is a covalent, reversible inhibitor of the NS3-4A protease (unlike BILN 2061which is a noncovalent inhibitor), with a slow-binding and slow-dissociation mechanism.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Determination of anti-HCV activity Stable Huh-7 cells containing the self-replicating, subgenomic HCV replicon, which is identical in sequence to the I377neo/NS3-3'/wt replicon are used for anti-HCV assays. Replicon cells are incubated at 37 °C for the indicated period of time with Telaprevir serially diluted in DMEM plus 2% FBS and 0.5% dimethyl sulfoxide (DMSO). Total cellular RNA is extracted using an RNeasy-96 kit, and the copy number of HCV RNA is determined using a quantitative RTPCR (QRT-PCR) assay for the assessment of 50% inhibitory concentration (IC50

細胞アッセイ: [1]

細胞系 Huh-7, HepG2, and peripheral blood mononuclear cells (PBMC)
濃度 Dissolved in DMSO, final concentration ~1 mM
処理時間 48 hours
方法 Cells are incubated with various concentrations of Telaprevir for 48 hours. Cell viability is determined by using a tetrazolium (MTS)-based cell viability assay.

動物実験: [2]

動物モデル SCID mice injected with recombinant adenovirus (Ad-WT-HCVpro-SEAP or Ad-MT-HCVpro-SEAP)
製剤 Formulated in polyvinylpyrrolidone (PVP) K-30 plus 2% sodium lauryl sulfate
投薬量 ~300 mg/kg
管理 Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Telaprevir (VX-950) SDF
分子量 679.85
化学式

C36H53N7O6

CAS No. 402957-28-2
保管 2年-20℃
6月-80℃in solvent
別名 LY-570310, MP-424
溶解度 (25°C) * In vitro DMSO 136 mg/mL (200.04 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide

カスタマーレビュー (4)


Click to enlarge
Rating
Source Antimicrob Agents Chemother, 2014, 10.1128/AAC.04220-14. Telaprevir (VX-950) purchased from Selleck
Method Crystal violet
Cell Lines HCV replicon genotype 1b cells
Concentrations 0.6, 1.5, 3, 6 uM
Incubation Time 28 days
Results The presence of miravirsen resulted in the decrease in the rate of cell expansion and a reduction in HCV RNA without the emergence of distinct clonal populations following the initial 25 days of passage at concentrations up to 20-fold the average EC50 (10 uM). In contrast, selection in the presence of telaprevir resulted in the decrease in the rate of cell expansion with the appearance of distinct individual resistant clonal populations.

Click to enlarge
Rating
Source Virology, 2013, 435(2), 385-94. Telaprevir (VX-950) purchased from Selleck
Method Coimmunoprecipitation analysis
Cell Lines 293 cells
Concentrations 0.2 mM
Incubation Time 1 days
Results These results suggest that DDB1 is a bona fide cellular substrate of NS3/4A. To confirm that DDB1 is cleaved by NS3/4A protease activity, we constructed a N-terminal and a C-terminal Flag-tagged DDB1 expression plasmid respectively. We found that NS3/4A cleavage resulted in a ~45 kDa N-terminal fragment and a ∼82 kDa C-terminal fragment. The added molecular size of these two fragments is consistent with the expected size of 127 kDa of the full-length DDB1. The cleavage of DDB1 by NS3/4A was inhibited by the NS3/4A inhibitor VX-950.

Click to enlarge
Rating
Source PLoS One, 2013, 8(12), e82094. Telaprevir (VX-950) purchased from Selleck
Method CBB staining
Cell Lines HCV replicon genotype 1b cells
Concentrations 0-500 uM
Incubation Time 28 days
Results It tested the effect of VX950, a specific inhibitor of NS3/4A protease, on C4 cleavage by NS3/4A protease and inhibition of complement activation. As shown in Figure, under a condition in which more than 80% of 32-kDa C4γ was processed into 17- and 15-kDa fragments in the presence of NS3/4A protease (lanes 5), pretreatment of the protease with 1 uM VX950 moderately inhibited the cleavage of C4γ (lanes 4). The NS3/4A-mediated processing of C4γ into 17- and 15-kDa fragments was almost completely blocked by VX950 at ≥10 uM (lanes 1-3).

Click to enlarge
Rating
Source 2011, Dr. Julie Sheldon,Dr Esteban Domingo and Dr Celia Perales. Telaprevir (VX-950) purchased from Selleck
Method MTT assays
Cell Lines
Concentrations 50 μM
Incubation Time 72 h
Results The 50% cytotoxic concentration (CC50) of VX-950 was 22 ± 3.2 μM.

製品表彰状 (10)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related HCVプロテアーゼ 阻害剤

  • Ledipasvir (GS5885)

    Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

  • SB-3CT

    SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

  • Leupeptin Hemisulfate

    Leupeptin Hemisulfate is a reversible inhibitor of serine and cysteine proteases.

  • MG-101 (ALLN)

    MG-101 (ALLN) is a cell-permeable and potent inhibitor of cysteine proteases including calpains and lysosomal cathepsins.

  • Danoprevir (ITMN-191)

    Danoprevir (ITMN-191)はB型肝炎ウイルス(HCV)のNS3/4Aプロティナーゼの模擬阻害剤、 IC50 が 0.2-3.5 nM.

    Features:A peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV).

  • Daclatasvir (BMS-790052)

    Daclatasvir (BMS-790052) は一流、高選択性の C型肝炎ウイルス(HCV)阻害剤、EC50 が9–50 pM.

    Features:First-in-class, highly selective inhibitor of hepatitis C virus (HCV) NS5A with picomolar EC50 values.

  • VX-222 (VCH-222, Lomibuvir)

    VX-222 (VCH-222, Lomibuvir)は新型有効と選択の非核苷ポリメラーゼ阻害剤、C型肝炎ウイルス(HCV)RNA依存のRNAポリメラーゼを抑制する時、 IC50 が 0.94-1.2 μMになる.

    Features:A novel, potent and selective inhibitor of non-nucleoside polymerase, specifically the HCV RNA-dependent RNA polymerase.

  • MG-132

    MG-132は、100nMのIC50によるプロテアソームの強力な阻害剤です。

  • Bortezomib (PS-341)

    Bortezomib (PS-341)は、強力なプロテアソーム阻害剤で、Kiが0.6nMです。

最近見られたアイテム

Tags: Telaprevir (VX-950)を買う | Telaprevir (VX-950)供給者 | Telaprevir (VX-950)を購入する | Telaprevir (VX-950)費用 | Telaprevir (VX-950)生産者 | オーダーTelaprevir (VX-950) | Telaprevir (VX-950)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ